Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing STS101 as an important and differentiated therapeutic option for the acute treatment of migraine.
Trending at Lumira Ventures
Specific Biologics is an early-stage biotechnology company on a mission to develop novel gene editing technologies to treat diseases through precision gene editing
Swift Medical is a leader in imaging technology and data analytics solutions for the healthcare industry. Swift Wound, together with Swift’s Metrics dashboard, represents a new generation in wound care management technology.
Thryv Therapeutics is developing therapies for genetic heart diseases pioneering a precision medicine approach to treat patients with Long QT Syndrome and potentially other arrhythmias.
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease.
X4 Pharmaceuticals, Inc is a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with rare immune system disorders.
Aurinia Pharmaceuticals lead drug, LUPKYNIS (voclosporin), was approved in January 2021 as the first oral therapy for lupus nephritis, a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death
Bardy Diagnostics, an innovator in digital health and remote patient monitoring, with a focus on providing the most diagnostically-accurate and patient-friendly cardiac patch and other monitors to the industry was acquired by Hillrom for $375 million in January 2021
Engage Therapeutics is focused on epilepsy patients suffering from uncontrolled seizures with what could be the first rescue treatment with the potential to stop their seizures. The company was acquired by UBC for up to US$270 million in June 2020. …
Essa Pharmaceuticals is a clinical stage company developing a small molecule therapy to overcome the issue of drug resistance for patients with prostate cancer.
Forbius is a clinical stage company that designs and develops biotherapeutics for treatment of cancer and fibrosis. The company was acquired by Bristol Myers Squibb in August 2020.
MAKO Surgical Corp.
Lumira was an early investor in MAKO Surgical Corp. prior to its IPO and later when it was acquired by Stryker for $1.65 billion in 2013 for its minimally invasive robotic surgical arm for partial knee and total hip arthroplasty.
Pharmasset was acquired by Gilead in 2011 for $11 billion for their oral therapeutics for the treatment of hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
Zymeworks is a biotherapeutics company that is developing best-in-class Azymetric™ bi-specific antibodies and antibody drug conjugates for the treatment of cancer, autoimmune and inflammatory diseases.
Alveolus, developer of next generation non-vascular interventional stent technology for use in the lungs, was acquired by Merit Medical Systems Inc. in February 2008.